Recommended Doses for Treating Typhoid Fever
For adults with typhoid fever, the recommended treatment is ciprofloxacin 500 mg orally twice daily for 10 days, or alternatively ceftriaxone 75 mg/kg/day (maximum 2-4 g/day) intravenously for 5-7 days. 1, 2, 3
Adult Treatment Regimens
First-line Options:
- Fluoroquinolones:
Alternative Options:
Cephalosporins:
Macrolides:
- Azithromycin: Recommended when fluoroquinolone resistance is suspected 4
Pediatric Treatment Regimens
Children ≥10 years:
- Fluoroquinolones:
Children <10 years:
- Ceftriaxone: 75 mg/kg/day IV (maximum 2 g/day) in two divided doses until defervescence, then continue for 5 additional days 2
- Ciprofloxacin: 10 mg/kg IV every 8-12 hours or 15 mg/kg orally every 8-12 hours (maximum 500 mg/dose) 4
Special Considerations
For Severe or Complicated Infections:
- Consider dual therapy with two distinct classes of antimicrobials for initial treatment 4
- Longer duration of therapy (14 days) may be required for severe infections 1
For Multidrug-Resistant Strains:
- Fluoroquinolones remain first-line if the organism is susceptible 4
- Azithromycin is recommended when fluoroquinolone resistance is suspected 4
- Ceftriaxone has shown efficacy against resistant strains with rapid blood culture clearance 3
Clinical Response Monitoring
- Mean defervescence time with ceftriaxone treatment is approximately 4-5.4 days 2, 5
- Blood cultures typically become negative within 3 days of starting ceftriaxone therapy 3
- Monitor for clinical improvement and consider changing therapy if no response after 5 days 3
Important Caveats
- Local resistance patterns should guide antimicrobial selection, as resistance to fluoroquinolones is increasing, particularly in South Asia 6
- Cefixime may be less effective than fluoroquinolones with longer time to defervescence 6
- Ceftriaxone appears to have similar efficacy to azithromycin but may lead to faster defervescence 6
- Patients treated with ceftriaxone may have prolonged fever despite negative blood cultures 3
- Chloramphenicol is no longer recommended as first-line therapy due to higher relapse rates compared to ceftriaxone 2, 3